Nicolas Charloteaux - 28 Sep 2020
The global pharmaceutical industry has made the commitment to ensure vaccines against covid-19 will be accessible to everyone that needs them. We are expanding our manufacturing capabilities and sharing available capacity to ramp up production to help meet high demand worldwide.
Allocation of new vaccines is determined by the regulatory authorities in each country that review and decide to license vaccines for recommended populations and under specific pricing, reimbursement or public funding programs, in part based on submissions from the manufacturers and in consultation with public health experts.
Read our commitments to tackling coronavirus pandemic here.